drug combinations

dart board miss failure

Fierce Pharma

Merck's Welireg surprisingly fails in first-line kidney cancer

Welireg's phase 3 flop in first-line kidney cancer comes as a surprise following two late-stage trial wins in the second-line and adjuvant settings.

Angus Liu Apr 21, 2026 10:00am

Terminated contract

Boundless scraps combo treatment of 2 unimpressive cancer drugs

Jan 20, 2026 9:00am

Cartoon of businessmen standing around a broken target

Arcus halts Gilead-partnered TIGIT trials as it reworks R&D

Dec 12, 2025 10:00am

graphic image of different colored hands shaking

Crescent inks $80M Kelun deal, adding ADC to mix with bispecific

Dec 4, 2025 9:50am

Graphic image of an arrow nailing the bullseye of a target

Exelixis beats Bayer drug in cancer trial, sending stock higher

Jun 23, 2025 7:30am

Large layoffs of employees Wooden figures of people going to the exit

Boundless Bio lays off 33% of staff as lead program stumbles

May 27, 2025 8:40am